DAIKI MIKI

Last Updated :2025/04/03

Affiliations, Positions
Graduate School of Biomedical and Health Sciences(Medical), Associate Professor
Web Site
https://researchmap.jp/daikimiki/?lang=english
E-mail
daikimikihiroshima-u.ac.jp
Self-introduction
I have focused on investigating host genetic factors involved in various liver diseases, such as chronic HBV and HCV infection, HCV-induced liver cirrhosis and cancer, and responsiveness to therapy (Nat Genet 2010*, Nat Genet 2011*, J Hepatol 2013, PLoS One 2013*; Nat Genet 2020, J Gastroenterol 2020*, *1st author). I have studied not only the human genome polymorphism but also the HCV genome mutation, and suggested the possibility of their interaction (J Hepatol 2015). Based on these experiences, I start to analyze the genome of gut bacteria which may be implicated in the pathogenesis of liver and metabolic disorders. In order to clarify the effects of them on the immune system and metabolic pathways, I conduct the integrated genetic and genomic analyses of human, virus and microbiota in the current study. Our goals are (1) establishment of precision medicine for various digestive diseases and (2) contribution to development of new therapies, diagnostic method, and prophylactic approach to various digestive diseases.

Basic Information

Major Professional Backgrounds

  • 2000/04, 2002/03, Hiroshima University Hospital, Resident
  • 2002/04, 2005/03, Mitsubishi-Mihara Hospital, Clinical Fellow
  • 2005/04, 2006/03, Hiroshima University Hospital, Clinical Fellow
  • 2008/10, 2010/03, The Institute of Medical Science, The University of Tokyo, Human Genome Center, Research Assistant
  • 2010/04, 2014/07, Center for Genomic Medicine, RIKEN, Laboratory for Digestive Diseases, Postdoctoral Researcher
  • 2014/08, 2018/03, RIKEN Center for Integrative Medical Sciences, Laboratory for Digestive Diseases, Deputy Team Leader
  • 2018/04/01, 2019/03/31, Hiroshima University, Graduate School of Biomedical & Health Sciences, Lecturer
  • 2019/04/01, 2024/05/31, Hiroshima University, Graduate School of Biomedical and Health Sciences, Lecturer

Educational Backgrounds

  • Hiroshima University, Faculty of Medicine, Japan, 1994/04, 2000/03
  • Hiroshima University, Graduate School of Biomedical Sciences, Japan, 2006/04, 2010/03

Academic Degrees

  • Doctor of Philosophy in Medical Sciences, Hiroshima University

Educational Activity

  • [Bachelor Degree Program] School of Medicine : Program of Medicine : Medicine
  • [Doctoral Program] Graduate School of Biomedical and Health Sciences : Division of Biomedical Sciences : Program of Medicine

Research Fields

  • Medicine,dentistry, and pharmacy;Clinical internal medicine;Gastroenterology
  • Biological Sciences;Genome science;Medical genome science
  • Medicine,dentistry, and pharmacy;Basic medicine;Virology

Research Keywords

  • Gastroenterology
  • Hepatology
  • Genome
  • hepatitis virus

Affiliated Academic Societies

  • The Japanese Society of Gastroenterology
  • The Japanese Society of Hepatology
  • The Japanese Cancer Association
  • The Japanese Society of Gastrointestinal Cancer Screening
  • The Japan Gastroenterological Endoscopy Society
  • The Japan Society of Human Genetics
  • Japanese Society of Medical Oncology
  • The Molecular Biology Society of Japan
  • The Japanese Society of Internal Medicine
  • Japanese Association for Cancer Detection and Diagnosis
  • The Liver Cancer Study Group of Japan
  • The Japanese Association for RNA interference

Educational Activity

Course in Charge

  1. 2025, Graduate Education (Master's Program) , 3Term, Data Literacy in Medicine
  2. 2025, Graduate Education (Doctoral Program) , 3Term, Utilization of data Literacy in Medicine
  3. 2025, Undergraduate Education, Year, Clinical diagnosis and treatment I
  4. 2025, Graduate Education (Doctoral Program) , First Semester, Advanced Seminar on Gastroenterology
  5. 2025, Graduate Education (Doctoral Program) , Second Semester, Advanced Seminar on Gastroenterology
  6. 2025, Graduate Education (Doctoral Program) , First Semester, Advanced Research on Gastroenterology
  7. 2025, Graduate Education (Doctoral Program) , Second Semester, Advanced Research on Gastroenterology

Research Activities

Academic Papers

  1. ★, Multi-omics analysis of a fatty liver model using human hepatocyte chimeric mice, SCIENTIFIC REPORTS, 14(1), 20240209
    Link to Paper Search Results by DOI
  2. Impact of MAFLD criteria on postoperative recurrence of non-B, non-C HCC, EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 36(4), 430-437, 202404
    Link to Paper Search Results by DOI
  3. Peripheral T Cell Subpopulations as a Potential Surrogate Biomarker during Atezolizumab plus Bevacizumab Treatment for Hepatocellular Carcinoma, CANCERS, 16(7), 202404
    Link to Paper Search Results by DOI
  4. The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib, ONCOLOGY, 101(8), 491-501, 202308
    Link to Paper Search Results by DOI
  5. Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus, JOURNAL OF GASTROENTEROLOGY, 58(12), 1211-1221, 202312
    Link to Paper Search Results by DOI
  6. Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma, CANCER MEDICINE, 13(5), 202403
    Link to Paper Search Results by DOI
  7. Clinical Outcomes of Switching from Zoledronic Acid to Denosumab for the Management of Severe Bone Metastasis from Hepatocellular Carcinoma: A Single-Center, Open-Label, Prospective Intervention Trial, YONAGO ACTA MEDICA, 66(4), 422-431, 202311
    Link to Paper Search Results by DOI
  8. Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma, CANCERS, 15(22), 202311
    Link to Paper Search Results by DOI
  9. Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma, COMMUNICATIONS MEDICINE, 3(1), 20231025
    Link to Paper Search Results by DOI
  10. Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failure, HEPATOLOGY INTERNATIONAL, 17(5), 1225-1232, 202310
    Link to Paper Search Results by DOI
  11. Correlation between serum pro-inflammatory cytokine levels and the prognosis of the patients with acute liver failure, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 38(9), 1637-1646, 202309
    Link to Paper Search Results by DOI
  12. Association of Hepatobiliary Phase of Gadoxetic-Acid-Enhanced MRI Imaging with Immune Microenvironment and Response to Atezolizumab Plus Bevacizumab Treatment, CANCERS, 15(17), 202309
    Link to Paper Search Results by DOI
  13. Sodium-glucose cotransporter-2 inhibitors improve FibroScan-aspartate aminotransferase scores in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes, EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 35(9), 989-996, 202309
    Link to Paper Search Results by DOI
  14. Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein, CANCERS, 15(8), 202304
    Link to Paper Search Results by DOI
  15. Hepatitis B Virus (HBV) Upregulates TRAIL-R3 Expression in Hepatocytes Resulting in Escape From Both Cell Apoptosis and Suppression of HBV Replication by TRAIL, JOURNAL OF INFECTIOUS DISEASES, 227(5), 686-695, 20230301
    Link to Paper Search Results by DOI
  16. Acute liver injury in a non-alcoholic fatty liver disease patient with chloroform exposure: a case report, CLINICAL JOURNAL OF GASTROENTEROLOGY, 16(2), 250-253, 202304
    Link to Paper Search Results by DOI
  17. Evaluation of atezolizumab plus bevacizumab combination therapy for hepatocellular carcinoma using contrast-enhanced ultrasonography, JOURNAL OF MEDICAL ULTRASONICS, 50(1), 57-62, 202301
    Link to Paper Search Results by DOI
  18. Low-Dose Alcohol-Induced Inhibition of Mouse Orthotopically Transplanted Tumors Is Associated with T-Cell Response, PATHOBIOLOGY, 90(1), 22-30, 202301
    Link to Paper Search Results by DOI
  19. Hepatic venous pressure gradient after balloon-occluded retrograde transvenous obliteration and liver stiffness measurement predict the prognosis of patients with gastric varices, BMC GASTROENTEROLOGY, 22(1), 20221222
    Link to Paper Search Results by DOI
  20. The presence of vessels encapsulating tumor clusters is associated with an immunosuppressive tumor microenvironment in hepatocellular carcinoma, INTERNATIONAL JOURNAL OF CANCER, 151(12), 2278-2290, 20221215
    Link to Paper Search Results by DOI
  21. The effect of the skin-liver capsule distance on the accuracy of ultrasound diagnosis for liver steatosis and fibrosis, JOURNAL OF MEDICAL ULTRASONICS, 49(3), 443-450, 202207
    Link to Paper Search Results by DOI
  22. Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection, JOURNAL OF GASTROENTEROLOGY, 57(9), 676-683, 202209
    Link to Paper Search Results by DOI
  23. The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment, PLOS ONE, 17(1), 20220118
    Link to Paper Search Results by DOI
  24. Establishment of a Monoclonal Antibody against Human NTCP That Blocks Hepatitis B Virus Infection, JOURNAL OF VIROLOGY, 96(5), 20220309
    Link to Paper Search Results by DOI
  25. Construction of an anti-hepatitis B virus preS1 antibody and usefulness of preS1 measurement for chronic hepatitis B patients Anti-HBV PreS1 antibody, JOURNAL OF INFECTION, 84(3), 391-399, 202203
    Link to Paper Search Results by DOI
  26. Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients, JOURNAL OF VIRAL HEPATITIS, 28(9), 1304-1311, 202109
    Link to Paper Search Results by DOI
  27. Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study, BMC GASTROENTEROLOGY, 21(1), 20210731
    Link to Paper Search Results by DOI
  28. ★, Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib, JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 40(1), 20210626
    Link to Paper Search Results by DOI
  29. Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 559, 78-83, 20210625
    Link to Paper Search Results by DOI
  30. Extracellular water to total body water ratio obtained by bioelectrical impedance analysis determines the dose intensity of lenvatinib for the treatment of patients with advanced hepatocellular carcinoma, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 36(6), 1685-1693, 202106
    Link to Paper Search Results by DOI
  31. ★, Clinical Usefulness of Serum Autotaxin for Early Prediction of Relapse in Male Patients with Type 1 Autoimmune Pancreatitis, DIGESTIVE DISEASES AND SCIENCES, 66(4), 1268-1275, 202104
    Link to Paper Search Results by DOI
  32. Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis, JOURNAL OF VIRAL HEPATITIS, 28(3), 538-547, 202103
    Link to Paper Search Results by DOI
  33. Abatacept treatment for patients with severe acute hepatitis caused by hepatitis B virus infection-Pilot study, JOURNAL OF VIRAL HEPATITIS, 28(2), 400-409, 202102
    Link to Paper Search Results by DOI
  34. ★, Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study, JOURNAL OF GASTROENTEROLOGY, 56(1), 67-77, 202101
    Link to Paper Search Results by DOI
  35. In vitro analysis of hepatic stellate cell activation influenced by transmembrane 6 superfamily 2 polymorphism, MOLECULAR MEDICINE REPORTS, 23(1), 202101
    Link to Paper Search Results by DOI
  36. Signal Activation of Hepatitis B Virus-Related Hepatocarcinogenesis by Up-regulation of SUV39h1, JOURNAL OF INFECTIOUS DISEASES, 222(12), 2061-2070, 20201215
    Link to Paper Search Results by DOI
  37. ★, PNPLA3andHLA-DQB1polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication, JOURNAL OF GASTROENTEROLOGY, 55(12), 1162-1170, 202012
    Link to Paper Search Results by DOI
  38. Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients, HEPATOLOGY RESEARCH, 50(11), 1222-1233, 202011
    Link to Paper Search Results by DOI
  39. Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis, HEPATOLOGY RESEARCH, 50(11), 1234-1243, 202011
    Link to Paper Search Results by DOI
  40. Risk factors for histological progression of non-alcoholic steatohepatitis analyzed from repeated biopsy cases, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 35(8), 1412-1419, 202008
    Link to Paper Search Results by DOI
  41. PD1 gene polymorphism is associated with a poor prognosis in hepatocellular carcinoma following liver resection, cohort study, INTERNATIONAL JOURNAL OF SURGERY, 80, 84-90, 202008
    Link to Paper Search Results by DOI
  42. ★, Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases, NATURE GENETICS, 52(7), 669-+, 202007
    Link to Paper Search Results by DOI
  43. ★, Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib, THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 12, 202005
    Link to Paper Search Results by DOI
  44. Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma, CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 11, 202005
  45. Comparative study on the replication of HCV1b genome between wild-type and cell culture-adaptive mutant in regard to sensitivities against anti-HCV drugs, MICROBIOLOGY AND IMMUNOLOGY, 64(4), 296-303, 202004
    Link to Paper Search Results by DOI
  46. Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy, JOURNAL OF MEDICAL VIROLOGY, 92(2), 210-218, 202002
    Link to Paper Search Results by DOI
  47. Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis, BMC GASTROENTEROLOGY, 19(1), 20191024
    Link to Paper Search Results by DOI
  48. Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice, JOURNAL OF GASTROENTEROLOGY, 54(7), 650-659, 201907
    Link to Paper Search Results by DOI
  49. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice., Journal of General Virology, 100(7), 1123-1131, 201907
  50. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy, JOURNAL OF MEDICAL VIROLOGY, 91(4), 650-658, 201904
    Link to Paper Search Results by DOI
  51. Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis, HEPATOLOGY COMMUNICATIONS, 3(3), 348-355, 201903
    Link to Paper Search Results by DOI
  52. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures, JOURNAL OF GASTROENTEROLOGY, 54(3), 291-296, 201903
    Link to Paper Search Results by DOI
  53. Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes, VIROLOGY, 525, 48-61, 201812
    Link to Paper Search Results by DOI
  54. Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C., Journal of Medical Virology, 90(12), 1834-1840, 201812
  55. CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients., Journal of Viral Hepatitis, 25(12), 1555-1564, 201812
  56. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure, JOURNAL OF GENERAL VIROLOGY, 99(8), 1058-1065, 201808
    Link to Paper Search Results by DOI
  57. Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 500(2), 152-157, 20180602
    Link to Paper Search Results by DOI
  58. ★, Serial profiling of circulating tumor DNA for optimization of anti-VEGF chemotherapy in metastatic colorectal cancer patients, INTERNATIONAL JOURNAL OF CANCER, 142(7), 1418-1426, 20180401
    Link to Paper Search Results by DOI
  59. Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus-related cirrhosis, HEPATOLOGY RESEARCH, 48(4), 264-274, 201803
    Link to Paper Search Results by DOI
  60. ★, Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease, JOURNAL OF GASTROENTEROLOGY, 53(2), 269-280, 201802
    Link to Paper Search Results by DOI
  61. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy, JOURNAL OF GASTROENTEROLOGY, 53(1), 107-118, 201801
    Link to Paper Search Results by DOI
  62. Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study, ANTIVIRAL THERAPY, 23(8), 639-646, 2018
    Link to Paper Search Results by DOI
  63. The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients., Antiviral Therapy, 23(3), 239-248, 2018
  64. Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients, JOURNAL OF MEDICAL VIROLOGY, 89(11), 1963-1972, 201711
    Link to Paper Search Results by DOI
  65. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(9), e00725-17-e00725-17, 201709
    Link to Paper Search Results by DOI
  66. The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy, PLOS ONE, 12(8), e0182710-e0182710, 20170810
    Link to Paper Search Results by DOI
  67. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(6), e00183-e00183, 201706
    Link to Paper Search Results by DOI
  68. Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology, JOURNAL OF GENERAL VIROLOGY, 98(5), 1040-1047, 201705
    Link to Paper Search Results by DOI
  69. Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C, JOURNAL OF GASTROENTEROLOGY, 52(4), 504-511, 201704
    Link to Paper Search Results by DOI
  70. Efficacy and Safety of Daclatasvir Plus Asunaprevir Therapy for Chronic Hepatitis C Patients With Renal Dysfunction, JOURNAL OF MEDICAL VIROLOGY, 89(4), 665-671, 201704
    Link to Paper Search Results by DOI
  71. Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 32(3), 645-650, 201703
    Link to Paper Search Results by DOI
  72. IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C, HEPATOLOGY RESEARCH, 47(3), E5-E13, 201703
    Link to Paper Search Results by DOI
  73. Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing, JOURNAL OF INFECTIOUS DISEASES, 214(11), 1687-1694, 20161201
    Link to Paper Search Results by DOI
  74. Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection, JOURNAL OF GASTROENTEROLOGY, 51(11), 1073-1080, 201611
    Link to Paper Search Results by DOI
  75. Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report, HEPATOLOGY RESEARCH, 46(9), 944-948, 201608
    Link to Paper Search Results by DOI
  76. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 31(5), 1009-1015, 201605
    Link to Paper Search Results by DOI
  77. Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones, JOURNAL OF INFECTION, 72(1), 91-102, 201601
    Link to Paper Search Results by DOI
  78. Common Variant Near HEY2 Has a Protective Effect on Ventricular Fibrillation Occurrence in Brugada Syndrome by Regulating the Repolarization Current, CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 9(1), e003436-e003436, 201601
    Link to Paper Search Results by DOI
  79. Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice, ANTIVIRAL THERAPY, 21(4), 307-315, 2016
    Link to Paper Search Results by DOI
  80. ★, Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A, JOURNAL OF HEPATOLOGY, 63(3), 554-563, 201509
    Link to Paper Search Results by DOI
  81. ★, Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy, CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY, 1(5), 516-534, 201509
    Link to Paper Search Results by DOI
  82. Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay, PLOS ONE, 10(6), e0130022-e0130022, 20150617
    Link to Paper Search Results by DOI
  83. Differences in serum microRNA profiles in hepatitis B and C virus infection, JOURNAL OF INFECTION, 70(3), 273-287, 201503
    Link to Paper Search Results by DOI
  84. The effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 30(3), 619-627, 201503
    Link to Paper Search Results by DOI
  85. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1, JOURNAL OF VIRAL HEPATITIS, 22(2), 158-165, 201502
    Link to Paper Search Results by DOI
  86. Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism, JOURNAL OF VIRAL HEPATITIS, 22(2), 166-174, 201502
    Link to Paper Search Results by DOI
  87. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C, JOURNAL OF GASTROENTEROLOGY, 49(12), 1548-1556, 201412
    Link to Paper Search Results by DOI
  88. ★, Quantitative Effect of Natural Killer-Cell Licensing on Hepatocellular Carcinoma Recurrence after Curative Hepatectomy, CANCER IMMUNOLOGY RESEARCH, 2(12), 1142-1147, 201412
    Link to Paper Search Results by DOI
  89. Two patients treated with pegylated interferon/ribavirin/telaprevir triple therapy for recurrent hepatitis C after living donor liver transplantation, HEPATOLOGY RESEARCH, 44(12), 1259-1264, 201411
    Link to Paper Search Results by DOI
  90. Human microRNA hsa-miR-1231 suppresses hepatitis B virus replication by targeting core mRNA, JOURNAL OF VIRAL HEPATITIS, 21(9), E89-E97, 201409
    Link to Paper Search Results by DOI
  91. IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population, JOURNAL OF GENERAL VIROLOGY, 95(6), 1297-1306, 201406
    Link to Paper Search Results by DOI
  92. Ultradeep Sequencing Study of Chronic Hepatitis C Virus Genotype 1 Infection in Patients Treated with Daclatasvir, Peginterferon, and Ribavirin, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 58(4), 2105-2112, 201404
    Link to Paper Search Results by DOI
  93. ★, HLA-DQB1*03 Confers Susceptibility to Chronic Hepatitis C in Japanese: A Genome-Wide Association Study, PLOS ONE, 8(12), e84226-e84226, 20131220
    Link to Paper Search Results by DOI
  94. A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 441(1), 230-235, 20131108
    Link to Paper Search Results by DOI
  95. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients, JOURNAL OF GASTROENTEROLOGY, 48(10), 1188-1204, 201310
    Link to Paper Search Results by DOI
  96. Recent progress in the study of genetic variants associated with liver diseases, Journal of Japanese Society of Gastroenterology, 110(9), 1577-1590, 20130905
    Link to Paper Search Results by DOI
  97. ★, A Translational Study of Resistance Emergence Using Sequential Direct-Acting Antiviral Agents for Hepatitis C Using Ultra-Deep Sequencing, AMERICAN JOURNAL OF GASTROENTEROLOGY, 108(9), 1464-1472, 201309
    Link to Paper Search Results by DOI
  98. ★, Genetic Analyses Reveal a Role for Vitamin D Insufficiency in HCV-Associated Hepatocellular Carcinoma Development, PLOS ONE, 8(5), e64053-e64053, 20130529
    Link to Paper Search Results by DOI
  99. Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B, JOURNAL OF MEDICAL VIROLOGY, 85(5), 789-798, 201305
    Link to Paper Search Results by DOI
  100. ★, A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region, JOURNAL OF HEPATOLOGY, 58(5), 875-882, 201305
    Link to Paper Search Results by DOI
  101. Identification of a Functional Variant in the MICA Promoter Which Regulates MICA Expression and Increases HCV-Related Hepatocellular Carcinoma Risk, PLOS ONE, 8(4), e61279-e61279, 20130411
    Link to Paper Search Results by DOI
  102. A Nonsynonymous Polymorphism in Semaphorin 3A as a Risk Factor for Human Unexplained Cardiac Arrest with Documented Ventricular Fibrillation, PLOS GENETICS, 9(4), e1003364-e1003364, 201304
    Link to Paper Search Results by DOI
  103. A case of clonorchiasis complicated with the expansion of liver cyst, Journal of Japanese Society of Gastroenterology, 110(3), 456-464, 20130305
    Link to Paper Search Results by DOI
  104. Hepatitis B Virus-Specific miRNAs and Argonaute2 Play a Role in the Viral Life Cycle, PLOS ONE, 7(10), e47490-e47490, 20121016
    Link to Paper Search Results by DOI
  105. Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 27(9), 1467-1472, 201209
    Link to Paper Search Results by DOI
  106. ★, Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse, HEPATOLOGY, 56(2), 555-566, 201208
    Link to Paper Search Results by DOI
  107. IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients, JOURNAL OF GASTROENTEROLOGY, 47(7), 834-844, 201207
    Link to Paper Search Results by DOI
  108. ★, Hepatocellular carcinoma: Towards personalized medicine, CANCER SCIENCE, 103(5), 846-850, 201205
    Link to Paper Search Results by DOI
  109. ★, Serum PAI-1 is a novel predictor for response to pegylated interferon-a-2b plus ribavirin therapy in chronic hepatitis C virus infection, JOURNAL OF VIRAL HEPATITIS, 19(2), E126-E133, 201202
    Link to Paper Search Results by DOI
  110. Identification of novel HCV deletion mutants in chronic hepatitis C patients, ANTIVIRAL THERAPY, 17(8), 1551-1561, 2012
    Link to Paper Search Results by DOI
  111. Achievement of Sustained Viral Response after Switching Treatment from Pegylated Interferon alpha-2b to alpha-2a and Ribavirin in Patients with Recurrence of Hepatitis C Virus Genotype 1 Infection after Liver Transplantation: A Case Report, INTERVIROLOGY, 55(4), 306-310, 2012
    Link to Paper Search Results by DOI
  112. Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferon-sensitivity determining region, HEPATOLOGY RESEARCH, 41(11), 1126-1131, 201111
    Link to Paper Search Results by DOI
  113. ★, A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population, HUMAN MOLECULAR GENETICS, 20(19), 3884-3892, 20111001
    Link to Paper Search Results by DOI
  114. IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma, JOURNAL OF VIRAL HEPATITIS, 18(10), E550-E560, 201110
    Link to Paper Search Results by DOI
  115. Inverse Association of IL28B Genotype and Liver mRNA Expression of Genes Promoting or Suppressing Antiviral State, JOURNAL OF MEDICAL VIROLOGY, 83(9), 1597-1607, 201109
    Link to Paper Search Results by DOI
  116. Hepatitis C Virus Infection Suppresses the Interferon Response in the Liver of the Human Hepatocyte Chimeric Mouse, PLOS ONE, 6(8), e23856-e23856, 20110823
    Link to Paper Search Results by DOI
  117. ★, Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers, NATURE GENETICS, 43(8), 797-800, 201108
    Link to Paper Search Results by DOI
  118. ★, IL28B But Not ITPA Polymorphism Is Predictive of Response to Pegylated Interferon, Ribavirin, and Telaprevir Triple Therapy in Patients With Genotype 1 Hepatitis C, JOURNAL OF INFECTIOUS DISEASES, 204(1), 84-93, 20110701
    Link to Paper Search Results by DOI
  119. ★, IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy, JOURNAL OF HEPATOLOGY, 54(6), 1094-1101, 201106
    Link to Paper Search Results by DOI
  120. Common Genetic Polymorphism of ITPA Gene Affects Ribavirin-Induced Anemia and Effect of Peg-Interferon Plus Ribavirin Therapy, JOURNAL OF MEDICAL VIROLOGY, 83(6), 1048-1057, 201106
    Link to Paper Search Results by DOI
  121. ★, HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy, GUT, 60(2), 261-267, 201102
    Link to Paper Search Results by DOI
  122. ★, Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations, NATURE GENETICS, 42(10), 893-896, 201010
    Link to Paper Search Results by DOI
  123. ★, Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients, JOURNAL OF HEPATOLOGY, 53(3), 439-443, 201009
    Link to Paper Search Results by DOI
  124. Importance of Serum Concentration of Adefovir for Lamivudine-Adefovir Combination Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(8), 3205-3211, 201008
    Link to Paper Search Results by DOI
  125. HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice, JOURNAL OF GENERAL VIROLOGY, 91(7), 1854-1864, 201007
    Link to Paper Search Results by DOI
  126. G to A hypermutation of TT virus, VIRUS RESEARCH, 149(2), 211-216, 201005
    Link to Paper Search Results by DOI
  127. Effects of structural variations of APOBEC3A and APOBEC3B genes in chronic hepatitis B virus infection, HEPATOLOGY RESEARCH, 39(12), 1159-1168, 200912
    Link to Paper Search Results by DOI
  128. G-to-A Hypermutation in Hepatitis B Virus (HBV) and Clinical Course of Patients with Chronic HBV Infection, JOURNAL OF INFECTIOUS DISEASES, 199(11), 1599-1607, 20090601
    Link to Paper Search Results by DOI
  129. ★, Involvement of Epithelial Cell Transforming Sequence-2 Oncoantigen in Lung and Esophageal Cancer Progression, CLINICAL CANCER RESEARCH, 15(1), 256-266, 20090101
    Link to Paper Search Results by DOI
  130. Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice, JOURNAL OF GENERAL VIROLOGY, 89(9), 2108-2113, 200809
    Link to Paper Search Results by DOI
  131. ★, Clinicopathological features of elderly patients with hepatitis C virus-related hepatocellular carcinoma, JOURNAL OF GASTROENTEROLOGY, 43(7), 550-557, 200807
    Link to Paper Search Results by DOI
  132. Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: Seven cases, WORLD JOURNAL OF GASTROENTEROLOGY, 14(16), 2602-2608, 20080428
    Link to Paper Search Results by DOI
  133. Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma, JOURNAL OF GASTROENTEROLOGY, 42(10), 845-853, 200712
    Link to Paper Search Results by DOI
  134. Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma, LIVER INTERNATIONAL, 27(9), 1209-1216, 200711
    Link to Paper Search Results by DOI
  135. Bile Acid-induced Hepatic Stellate Cell Activativation, Japanese Pharmacology & Therapeutics, 33(supplement), S97-S100, 200512
  136. Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis, JOURNAL OF GASTROENTEROLOGY, 57(2), 120-132, 202202
    Link to Paper Search Results by DOI

Publications such as books

  1. 2021/12, Gastroenterology & Hepatology, 10(6): 718-723, Hepatocarcinogenesis after SVR and genetic polymorphisms, 2021, 12, Scholarly Book, Joint work, 日本語, Daiki Miki, Kazuaki Chayama, 718-723

Invited Lecture, Oral Presentation, Poster Presentation

  1. Posttreatment Child-Pugh class stratifies patient survival after direct-acting antiviral treatment in hepatitis C virus associated decompensated cirrhosis, Yuki Tahata, Hayato Hikita, Satoshi Mochida, Nobuyuki Enomoto, Akio Ido, Hidekatsu Kuroda, Daiki Miki, Masayuki Kurosaki, Yoichi Hiasa, Ryotaro Sakamori, Norifumi Kawada, Taro Yamashita, Goki Suda, Hiroshi Yatsuhashi, Hitoshi Yoshiji, Naoya Kato, Taro Takami, Kazuhiko Nakao, Kentaro Matsuura, Yasuhiro Asahina, Yoshito Itoh, Ryosuke Tateishi, Yasunari Nakamoto, Eiji Kakazu, Shuji Terai, Masahito Shimizu, Yoshiyuki Ueno, Norio Akuta, Takahiro Kodama, Tomohide Tatsumi, et al., The Liver Meeting 2023, 2023/11/10, Without Invitation, English, AASLD
  2. The Inpact of Bevacizumab Withdrawal on Prognosis in Atezolizmab + Bevacizumab Combiation Therapy for Unresectable Hepatocellular Carcinoma, Amioka K,Kawaoka T,Yano S,Naruto K,Yamaoka K,Uchikawa S,Fujino H,Nakahara T,Ono A,Murakami E,Miki D,Tsuge M,Oka S, APASL Oncology 2023 Sendai, 2023/10/27, Without Invitation, English, APASL
  3. Effectiveness of Repeated Stereotactic Body Radiation Therapy for Hepetocellular Carcinoma, Kawaoka T,Yano S,Shirane Y,Miura R,Naruto K,Amioka K,Fujii Y,Fujino H,Ono A,Nakahara T,Murakami E,Miki D,Tsuge M,Oka S, APASL Oncology 2023 Sendai, 2023/10/27, Without Invitation, English, APASL
  4. Post-treatment liver function, but not baseline liver function, predicts survival in hepatitis C virus patients with decompensated cirrhosis after direct-acting antiviral treatment, Yuki Tahata, Hayato Hikita, Satoshi Mochida, Nobuyuki Enomoto, Akio Ido, Hidekatsu Kuroda, Daiki Miki, Masayuki Kurosaki, Yoichi Hiasa, Ryotaro Sakamori, Norifumi Kawada, Taro Yamashita, Goki Suda, Hiroshi Yatsuhashi, Hitoshi Yoshiji, Naoya Kato, Taro Takami, Kazuhiko Nakao, Kentaro Matsuura, Yasuhiro Asahina, Yoshito Itoh, Ryosuke Tateishi, Yasunari Nakamoto, Eiji Kakazu, Shuji Terai, Masahito Shimizu, Yoshiyuki Ueno, Norio Akuta, Takahiro Kodama, Tomohide Tatsumi, et al., EASL Congress 2023, 2023/06/21, Without Invitation, English, EASL
  5. The real-world impact of direct-acting antiviral treatment on liver-related events in patients with hepatitis C virus-associated cirrhosis, Tahata Y, Hikita H, Mochida S, Enomoto N, Kawada N, Kurosaki M, Ido A, Miki D, Yoshiji H, Takikawa Y, Sakamori R, Hiasa Y, Nakao K, Kato N, Ueno Y, Yatsuhashi H, Itoh Y, Tateishi R, Suda G, Takami T, Yamashita T, Nakamoto Y, Asahina Y, Matsuura K, Kanto T, Akuta N, Terai S, Shimizu M, Yamada R, Kodama T, Tatsumi T, Yamada T, Takehara T, The Liver Meeting 2021, 2021/11/12, Without Invitation, English, American Association for the Study of Liver Diseases, Anaheim, USA
  6. NOVEL RESISTANCE-ASSOCIATED SUBSTITUTIONS AGAINST PIBRENTASVIR EMERGED IN GENOTYPE 1b HCV-INFECTED MICE, The Liver Meeting 2021, 2021/11/12, Without Invitation, English, American Association for the Study of Liver Diseases, Anaheim, USA
  7. CIRCULATING CELL-FREE TUMOR DNA ANALYSIS IN ADVANCED HEPATOCELLULAR CARCINOMA TREATED WITH LENVATINIB, The Liver Meeting 2021, 2021/11/12, Without Invitation, English, American Association for the Study of Liver Diseases, Anaheim, USA
  8. STEREOTACTIC BODY RADIATION THERAPY COMBINED WITH TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION FOR SMALL HEPATOCELLULAR CARCINOMA, The Liver Meeting 2021, 2021/11/12, Without Invitation, English, American Association for the Study of Liver Diseases, Anaheim, USA
  9. Risk stratification for HCC development after SVR using serum AFP level, Daiki Miki, Junko Tanaka, Kazuaki Chayama, JDDW2021, 2021/11/04, Without Invitation, Japanese, JDDW, Kobe, Japan
  10. Risk stratification for HCC development after SVR using serum AFP level, Daiki Miki, Hiroshi Aikata, Hatsue Fujino, Atsushi Ono, Masami Yamauchi, Masataka Tsuge, Kazuaki Chayama, The 80th Annual Meeting of the Japanese Cancer Association, 2021/09/30, Without Invitation, Japanese, Japanese Cancer Association, Yokohama, Japan
  11. Investigation of the effect of PNPLA3 polymorphism on the development of HCC after HCV eradication, Daiki Miki, Junko Tanaka, Kazuaki Chayama, The 57th Annual Meeting of the Japan Society of Hepatology, 2021/06/17, Without Invitation, Japanese, The Japan Society of Hepatology, Sapporo
  12. Improvement in serum albumin levels after direct acting antivirals treatment for patients with hepatitis C virus-related cirrhosis depends on the baseline serum albumin levels, Yuki Tahata, Hayato Hikita, Satoshi Mochida, Norifumi Kawada, Nobuyuki Enomoto, Akio Ido, Hitoshi Yoshiji, Daiki Miki, Yoichi Hiasa, Yasuhiro Takikawa, Ryotaro Sakamori, Masayuki Kurosaki, Hiroshi Yatsuhashi, Ryosuke Tateishi, Yoshiyuki Ueno, Yoshito Itoh, Taro Yamashita, Tatsuya Kanto, Goki Suda, Yasunari Nakamoto, Naoya Kato, Yasuhiro Asahina, Kentaro Matsuura, Shuji Terai, Kazuhiko Nakao, Masahito Shimizu, Taro Takami, Norio Akuta, Ryoko Yamada, Takahiro Kodama, Tomohide Tatsumi, Tomomi Yamada, Tetsuo Takehara, The Liver Meeting 2020, 2020/11/13, Without Invitation, English, American Association for the Study of Liver Diseases, Boston, USA
  13. The investigation of risk factors for the development of hepatocellular carcinoma after HCV eradication, Daiki Miki, Junko Tanaka, Kazuaki Chayama, JDDW2020, 2020/11/05, Without Invitation, Japanese, Organization of Japan Digestive Disease Week, Kobe, Japan
  14. Real-world evidence of multi-systemic therapy for hepatocellular carcinoma, Hiroshi Aikata, Masami Yamauchi, Atsushi Ono, Daiki Miki, Masataka Tsuge, Kazuaki Chayama, The 79th Annual Meeting of the Japanese Cancer Association, 2020/10/03, Without Invitation, Japanese, The Japanese Cancer Association, Hiroshima, Japan
  15. Genetic polymorphism in PNPLA3 is associated with hepatocellular carcinoma after hepatitis C virus eradication, Daiki Miki, Hiroshi Aikata, Hatsue Fujino, Atsushi Ono, Masami Yamauchi, Masataka Tsuge, Kazuaki Chayama, The 79th Annual Meeting of the Japanese Cancer Association, 2020/10/01, Without Invitation, Japanese, The Japanese Cancer Association, Hiroshima, Japan
  16. Tumor FGFR4 Level Predicts the Efficacy of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma, Masami Yamauchi, Atsushi Ono, Daiki Miki, Masataka Tsuge, Hiroshi Aikata, Kazuaki Chayama, The 79th Annual Meeting of the Japanese Cancer Association, 2020/10/01, Without Invitation, English, The Japanese Cancer Association, Hiroshima, Japan
  17. Exploratory analysis of biomarkers associated with clinical outcomes in advanced HCC patients receiving lenvatinib, Atsushi Ono, Masami Yamauchi, Daiki Miki, Masataka Tsuge, Hiroshi Aikata, Kazuaki Chayama, The 79th Annual Meeting of the Japanese Cancer Association, 2020/10/01, Without Invitation, Japanese, The Japanese Cancer Association, Hiroshima, Japan
  18. INVESTIGATION FOR THE CHARACTERISTIC PATTERNS OF GUT MICROBIOTA IN A WIDE RANGE OF LIVER DISEASES, Daiki Miki, Tomokazu Kawaoka, Kazuaki Chayama, The 106th General Meeting of the Japanese Society of Gastroenterology, 2020/08/11, Without Invitation, Japanese, The Japanese Society of Gastroenterology, Hiroshima, Japan
  19. Serum Autotaxin for Early Prediction of Relapse in Type 1 Autoimmune Pancreatitis, Ayami Fukiage, Hatsue Fujino, Daiki Miki, Yasutaka Ishii, Kazuaki Chayama, The 106th General Meeting of the Japanese Society of Gastroenterology, 2020/08/11, Without Invitation, Japanese, The Japanese Society of Gastroenterology, Hiroshima, Japan
  20. Serum autotaxin as a predictive marker for the progression of liver fibrosis and development of hepatocellular carcinoma in chronic HBV patients during nucleoside/nucleotide analogue therapy, Fujino H, Teraoka Y, Morio K, Ono A, Nakahara T, Murakami E, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Abe-Chayama H, Imamura M, Aikata H, Chayama K., The 106th General Meeting of the Japanese Society of Gastroenterology, 2020/08/11, Without Invitation, Japanese, The Japanese Society of Gastroenterology, Hiroshima, Japan
  21. A COMPREHENSIVE ANALYSIS OF A WIDE RANGE OF LIVER DISEASES BY 16S rRNA SEQUENCING REVEALS CHARACTERISTIC PATTERNS OF GUT MICROBIOTA IN EACH ETIOLOGY, Daiki Miki, Yumi Shimomura, Nelson Hayes, Hiromi Abe-Chayama, Hatsue Fujino, Maiko Numba, Takashi Nakahara, Atsushi Ono, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Hiroshi Aikata, Grace Naswa Makokha, Tatsuhiko Tsunoda, Kazuaki Chayama, The Liver Meeting 2019, 2019/11/11, Without Invitation, English, American Association for the Study of Liver Diseases, Boston, USA
  22. INDEPENDENT IMPACT OF POLYMORPHISM IN IRF5 AS WELL AS STAT4 ON HBV-RELATED HEPATOCARCINOGENESIS, Daiki Miki, Masataka Tsuge, Hiromi Abe-Chayama, Nelson Hayes, Hatsue Fujino, Grace Naswa Makokha, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Akira Hiramatsu, Michio Imamura, Hiroshi Aikata, Tatsuhiko Tsunoda, Kazuaki Chayama, The Liver Meeting 2019, 2019/11/11, Without Invitation, English, American Association for the Study of Liver Diseases, Boston, USA
  23. ASSOCIATION OF FNDC5, PNPLA3 AND TM6SF2 POLYMORPHISMS WITH HEPATIC STEATOSIS IN NAFLD PATIENTS, Daiki Miki, Takashi Nakahara, Eisuke Murakami, Hiromi Abe-Chayama, Hatsue Fujino, Atsushi Ono, Masami Yamauchi, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Hiroshi Aikata, Nelson Hayes, Grace Naswa Makokha, Tatsuhiko Tsunoda, Kazuaki Chayama, The Liver Meeting 2019, 2019/11/10, Without Invitation, English, American Association for the Study of Liver Diseases, Boston, USA
  24. DIFFERENTIAL EFFECTS OF HOST GENETIC FACTORS ON HCV PERSISTENCE ACCORDING TO HCV GENOTYPES, Daiki Miki, Tomokazu Kawaoka, Nelson Hayes, Hiromi Abe-Chayama, Hatsue Fujino, Grace Naswa Makokha, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Hiroshi Aikata, Tatsuhiko Tsunoda, Kazuaki Chayama, The Liver Meeting 2019, 2019/11/10, Without Invitation, English, American Association for the Study of Liver Diseases, Boston, USA
  25. RESISTANCE ANALYSIS FOR GLECAPREVIR AND PIBRENTASVIR ON GENOTYPE 1b HEPATITIS C VIRUS INFECTION IN SUBGENOMIC REPLICON SYSTEMS AND HUMAN HEPATOCYTE TRANSPLANTED MICE, Mitsutaka Osawa, Michio Imamura, Takuro Uchida, Yuji Teraoka, Hatsue Fujino, Takashi Nakahara, Atsushi Ono, Eisuke Murakami, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge, Akira Hiramatsu, Hiromi Abe-Chayama, Nelson Hayes, Grace Naswa Makokha, Hiroshi Aikata, Yuji Ishida, Chise Tateno, Yohei Miyayama, Makoto Hijikata, Kazuaki Chayama, The Liver Meeting 2019, 2019/11/10, Without Invitation, English, American Association for the Study of Liver Diseases, Boston, USA
  26. TUMOR AND BLOOD FGFR4 LEVELS PREDICT THE EFFICACY OF LENVATINIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA, Masami Yamauchi, Atsushi Ono, Haruna Hatooka, Kenichiro Kodama, Peiyi Zhang, Yuji Teraoka, Kei Morio, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Daiki Miki, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Clair Nelson Hayes, Hiroshi Aikata, Kazuaki Chayama, The Liver Meeting 2019, 2019/11/09, Without Invitation, English, American Association for the Study of Liver Diseases, Boston, USA
  27. PERMISSION OF HEPATITIS B VIRUS INFECTION IN Jak3KORag2KO MOUSE, Yuji Teraoka, Michio Imamura, Takuro Uchida, Kazuki Ohya, Mitsutaka Osawa, Kei Morio, Hatsue Fujino, Takashi Nakahara, Atsushi Ono, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Masataka Tsuge, Daiki Miki, Akira Hiramatsu, Hiromi Abe-Chayama, Nelson Hayes, Yuji Ishida, Chise Tateno, Hiroshi Aikata, Kazuaki Chayama, The Liver Meeting 2019, 2019/11/09, Without Invitation, English, American Association for the Study of Liver Diseases, Boston, USA
  28. GENETIC POLYMORPHISM OF IP-10, NOT IFNL4 OR HLA-DPS, AFFECTS LIVER INFLAMMATION IN CHRONIC HEPATITIS B PATIENTS, Daiki Miki, Masataka Tsuge, Hiromi Abe-Chayama, Nelson Hayes, Hatsue Fujino, Grace Naswa Makokha, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Akira Hiramatsu, Michio Imamura, Hiroshi Aikata, Tatsuhiko Tsunoda, Kazuaki Chayama, The Liver Meeting 2019, 2019/11/08, Without Invitation, English, American Association for the Study of Liver Diseases, Boston, USA
  29. EXPLORATORY ANALYSIS OF BIOMARKERS ASSOCIATED WITH CLINICAL OUTCOMES OF LENVATINIB IN HEPATOCELLULAR CARCINOMA, Atsushi Ono, Hiroshi Aikata, Masami Yamauchi, Kenichiro Kodama, Daiki Miki, Waka Ohishi, Yuji Teraoka, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Tomokazu Kawaoka, Hiromi Abe-Chayama, Masataka Tsuge, Michio Imamura, Clair Nelson Hayes, Kazuaki Chayama, The Liver Meeting 2019, 2019/11/08, Without Invitation, English, American Association for the Study of Liver Diseases, Boston, USA
  30. The SNP allele corresponding to higher IRF5 expression reduces susceptibility to HBV-related hepatocellular carcinoma, Daiki Miki, Masataka Tsuge, Masami Yamauchi, Atsushi Ono, Hiroshi Aikata, Tatsuhiko Tsunoda, Kazuaki Chayama, The 78th Annual Meeting of the Japanese Cancer Association, 2019/09/26, Without Invitation, English, Japanese Cancer Association, Kyoto, JAPAN
  31. Multiple genetic factors affecting nonalcoholic fatty liver disease and nonalcoholic steatohepatitis-related hepatocellular carcinoma in the Japanese population, Daiki Miki, Yuichi Hiyama, Atsushi Ono, Masami Yamauchi, Masataka Tsuge, Hiroshi Aikata, Tatsuhiko Tsunoda, Kazuaki Chayama, 11th AACR-JCA Joint Conference, 2019/02/10, Without Invitation, English, American Association for Cancer Research, Japanese Cancer Association, Hawaii, USA
  32. Association of TLL1 Polymorphism with Development of Hepatocellular Carcinoma after Hepatitis C Virus Eradication and Fibrosis Severity, Daiki Miki, Tomokazu Kawaoka, Yuko Nagaoki, Nelson Hayes, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Hiroshi Aikata, Hiromi Abe-Chayama, Hidenori Ochi, Tatsuhiko Tsunoda, Kazuaki Chayama, The Liver Meeting 2018, 2018/11/10, Without Invitation, English, American Association for the Study of Liver Diseases, San Francisco, USA
  33. Prevalence of NS5A Resistance Associated Variants in NS5A Inhibitor Treatment Failures and an Effective Treatment for NS5A-P32 Deleted Hepatitis C Virus in Humanized Mice, Yuji Teraoka, Takuro Uchida, Michio Imamura, Mitutaka Osawa, Tomokazu Kawaoka, Masataka Tsuge, Hiromi Abe-Chayama, Nelson Hayes, Grace Naswa Makokha, Hiroshi Aikata, Daiki Miki, Hidenori Ochi, Yuji Ishida, Chise Tateno, Kazuaki Chayama, The Liver Meeting 2018, 2018/11/09, Without Invitation, English, American Association for the Study of Liver Diseases, San Francisco, USA
  34. Host genetic factors affecting NAFLD/NASH-related HCC in the Japanese population, Daiki Miki, Masataka Tsuge, Masami Yamauchi, Hiroshi Aikata, Kazuaki Chayama, The 77th Annual Meeting of the Japanese Cancer Association, 2018/09/28, Without Invitation, Japanese, Japanese Cancer Association, Osaka, Japan
  35. Hepatitis B virus up-regulates IL8 expression via endoplasmic reticulum stress and leads to suppress interferon responsiveness, Tsuge, Masataka; Hiraga, Nobuhiko; Uchida, Takuro; Murakami, Eisuke; Abe-Chayama, Hiromi; Miki, Daiki; Imamura, Michio; Kawakami, Yoshiiku; Aikata, Hiroshi; Ochi, Hidenori; Chayama, Kazuaki, 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, 2017/10, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases (AASLD), Washington, D.C., USA
  36. Characterizing the early immune response to hepatitis B virus infection using the human hepatocyte chimeric mouse model, Hayes, Nelson; Akamatsu, Sakura; Tsuge, Masataka; Miki, Daiki; Abe-Chayama, Hiromi; Imamura, Michio; Chayama, Kazuaki, 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, 2017/10, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases (AASLD), Washington, D.C., USA
  37. Serum HMGB1 concentrations is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy, Ono, Atsushi; Masuda, Kazuhiko; Aikata, Hiroshi; Kawaoka, Tomokazu; Hayes, Nelson; Nakahara, Takashi; Miki, Daiki; Tsuge, Masataka; Hiramatsu, Akira; Imamura, Michio; Abe-Chayama, Hiromi; Kawakami, Yoshiiku; Ochi, Hidenori; Chayama, Kazuaki, 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, 2017/10, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases (AASLD), Washington, D.C., USA
  38. Hepatocellular carcinoma development in hepatitis C virus patients who achieved sustained viral response by interferon therapy and direct anti-viral agents therapy, Nagaoki, Yuko; Imamura, Michio; Nakamura, Yuki; Morio, Kei; Nakahara, Takashi; Kawaoka, Tomokazu; Tsuge, Masataka; Hiramatsu, Akira; Kawakami, Yoshiiku; Aikata, Hiroshi; Chayama, Kazuaki; Miki, Daiki, 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, 2017/10, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases (AASLD), Washington, D.C., USA
  39. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis, Nagaoki, Yuko; Aikata, Hiroshi; Nakamura, Yuki; Morio, Kei; Nakahara, Takashi; Kawaoka, Tomokazu; Miki, Daiki; Tsuge, Masataka; Hiramatsu, Akira; Imamura, Michio; Kawakami, Yoshiiku; Ochi, Hidenori; Chayama, Kazuaki, 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, 2017/10, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases (AASLD), Washington, D.C., USA
  40. Serial profiling of circulating tumor DNA identifies biomarkers for anti-VEGF chemotherapy in mCRC patients, Yamauchi, Masami; Chayama, Kazuaki; Urabe, Yuji; Ono, Atsushi; Ochi, Hidenori; Miki, Daiki, 2017 Annual Meeting of the Japanese-Society-of-Medical-Oncology, 2017/07, Without Invitation, English, Japanese-Society-of-Medical-Oncology, Kobe, Japan
  41. Evaluation of antiviral effects of a novel site-specific pegylated interferon beta using humanized mouse model, Tsuge, Masataka; Uchida, Takuro; Kan, Hiromi; Miki, Daiki; Imamura, Michio; Ochi, Hidenori; Hayes, C. Nelson; Shimozono, Reiko; Iwamura, Tomokatsu; Chayama, Kazuaki, 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), 2016/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases (AASLD), Boston, USA
  42. Protease inhibitor resistance remains even after mutant strains become undetectable using ultra-deep sequencing, Kan, Hiromi; Imamura, Michio; Hiraga, Nobuhiko; Hayes, C. Nelson; Uchida, Takuro; Miyaki, Eisuke; Tsuge, Masataka; Abe-Chayama, Hiromi; Aikata, Hiroshi; Miki, Daiki; Ochi, Hidenori; Ishida, Yuji; Tateno, Chise; Chayama, Kazuaki, 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), 2016/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases (AASLD), Boston, USA
  43. Japanese genetic study could not suggest the importance of the NTCP locus for HBV persistence, Miki D, Ochi H, Hayes CN, Abe H, Akamatsu S, Ono A, Nakahara T, Zhang Y, Masaki K, Fujino H, Miyaki E, Kan H, Uchida T, Hiraga N, Tsuge M, Kawaoka T, Imamura M, Kawakami Y, Aikata H, Chayama K, The 25th Conference of the Asian Pacific Association for the Study of the Liver, 2016/02/22, Without Invitation, English, Asian Pacific Association for the Study of the Liver (APASL), Tokyo, Japan
  44. The relationship between hepatocellular carcinoma development and reduced expression levels of the major germline genotype of PROSC, which is frequently deleted in hepatocellular carcinoma, Miki, Daiki; Ochi, Hidenori; Hayes, C. Nelson; Abe, Hiromi; Akamatsu, Sakura; Ono, Atsushi; Nakahara, Takashi; Zhang, Yizhou; Masaki, Keiichi; Fujino, Hatsue; Miyaki, Eisuke; Kan, Hiromi; Uchida, Takuro; Hiraga, Nobuhiko; Tsuge, Masataka; Kawaoka, Tomokazu; Imamura, Michio; Kawakami, Yoshiiku; Aikata, Hiroshi; Chayama, Kazuaki, 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), 2015/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases (AASLD), San Francisco, USA
  45. Circulating tumor DNA analysis for liver cancers and its usefulness as a liquid biopsy, Ono, Atsushi; Hayes, C. Nelson; Uchida, Takuro; Kan, Hiromi; Masaki, Keiichi; Nakahara, Takashi; Miki, Daiki; Kawaoka, Tomokazu; Tsuge, Masataka; Hiraga, Nobuhiko; Imamura, Michio; Kawakami, Yoshiiku; Aikata, Hiroshi; Ochi, Hidenori; Abe, Hiromi; Nakagawa, Hidewaki; Chayama, Kazuaki, 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), 2015/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases (AASLD), San Francisco, USA
  46. Rapid, sensitive, and accurate evaluation system for drug resistant strain (NS5A-Y93H) frequency in genotype 1b HCV, Ochi, Hidenori; Yoshimi, Satoshi; Murakami, Eisuke; Uchida, Takuro; Kan, Hiromi; Akamatsu, Sakura; Hayes, C. Nelson; Abe, Hiromi; Miki, Daiki; Hiraga, Nobuhiko; Imamura, Michio; Aikata, Hiroshi; Chayama, Kazuaki, 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), 2015/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases (AASLD), San Francisco, USA
  47. Genetic association study failed to confirm an association between the NTCP S267F mutation and persistence of hepatitis B virus or development of hepatocellular carcinoma in the Japanese population, Miki, Daiki; Ochi, Hidenori; Hayes, C. Nelson; Abe, Hiromi; Akamatsu, Sakura; Ono, Atsushi; Nakahara, Takashi; Zhang, Yizhou; Masaki, Keiichi; Fujino, Hatsue; Miyaki, Eisuke; Kan, Hiromi; Uchida, Takuro; Hiraga, Nobuhiko; Tsuge, Masataka; Kawaoka, Tomokazu; Imamura, Michio; Kawakami, Yoshiiku; Aikata, Hiroshi; Chayama, Kazuaki, 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), 2015/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases (AASLD), San Francisco, USA
  48. Genome-wide scan of miRNA polymorphisms revealed a suggestive association of miR-3143 with chronic hepatitis B virus infection, Miki, Daiki; Ochi, Hidenori; Hayes, C. Nelson; Abe, Hiromi; Akamatsu, Sakura; Ono, Atsushi; Nakahara, Takashi; Zhang, Yizhou; Masaki, Keiichi; Fujino, Hatsue; Miyaki, Eisuke; Kan, Hiromi; Uchida, Takuro; Hiraga, Nobuhiko; Tsuge, Masataka; Kawaoka, Tomokazu; Imamura, Michio; Kawakami, Yoshiiku; Aikata, Hiroshi; Chayama, Kazuaki, 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), 2015/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases (AASLD), San Francisco, USA
  49. Difference of intracellular responses by HBV genotype A and C infection in humanized mouse model, Tsuge, Masataka; Hiraga, Nobuhiko; Abe, Hiromi; Miki, Daiki; Imamura, Michio; Ochi, Hidenori; Hayes, C. Nelson; Chayama, Kazuaki, 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), 2015/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases (AASLD), San Francisco, USA
  50. The impact of HLA-DQs and IFNL4 variant on hepatitis C virus-induced liver inflammation, Miki, Daiki; Ochi, Hidenori; Hayes, C. Nelson; Abe, Hiromi; Akamatsu, Sakura; Ono, Atsushi; Nakahara, Takashi; Zhang, Yizhou; Masaki, Keiichi; Fujino, Hatsue; Miyaki, Eisuke; Kan, Hiromi; Uchida, Takuro; Hiraga, Nobuhiko; Tsuge, Masataka; Kawaoka, Tomokazu; Imamura, Michio; Kawakami, Yoshiiku; Aikata, Hiroshi; Chayama, Kazuaki, 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), 2015/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases (AASLD), San Francisco, USA
  51. Involvement of Endoplasmic Reticulum Stress Transducer BBF2H7 in Hepatocellular Carcinoma Promotion, Zhang, Yizhou; Hayes, Nelson; Tsuge, Masataka; Hiraga, Nobuhiko; Uchida, Takuro; Miki, Daiki; Abe, Hiromi; Chayama, Kazuaki, 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), 2015/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases (AASLD), San Francisco, USA
  52. The IL28B SNP has a stronger regulatory effect on the expression of OAS1 than a nearby SNP located downstream of OAS1 in chronic HCV patients, Miki, Daiki; Abe, Hiromi; Hayes, C. Nelson; Ochi, Hidenori; Kawaoka, Tomokazu; Akamatsu, Sakura; Ono, Atsushi; Nakahara, Takashi; Seki, Noriaki; Murakami, Eisuke; Zhang, Yizhou; Uchida, Takuro; Honda, Yohji; Masaki, Keiichi; Kan, Hiromi; Tsuge, Masataka; Hiraga, Nobuhiko; Imamura, Michio; Kawakami, Yoshiiku; Aikata, Hiroshi; Kubo, Michiaki; Chayama, Kazuaki, 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, 2014/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases, Boston, USA
  53. Pretreatment induction of ISGs in the presence of IFNL4 in hepatocytes but not in white blood cells is related with poor induction of ISGs following IFN-alpha therapy, Abe, Hiromi; Hayes, C. Nelson; Hiraga, Nobuhiko; Imamura, Michio; Tsuge, Masataka; Miki, Daiki; Aikata, Hiroshi; Ochi, Hidenori; Ishida, Yuji; Tateno, Chise; Yoshizato, Katsutoshi; Chayama, Kazuaki, 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, 2014/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases, Boston, USA
  54. A single amino acid substitution in HLA-DQB1 as well as an IFNL4 variant strongly affect susceptibility to chronic hepatitis C, Miki, Daiki; Ochi, Hidenori; Takahashi, Atsushi; Hayes, C. Nelson; Urabe, Yuji; Abe, Hiromi; Ono, Atsushi; Akamatsu, Sakura; Nakahara, Takashi; Seki, Noriaki; Murakami, Eisuke; Zhang, Yizhou; Uchida, Takuro; Honda, Yohji; Yoshimi, Satoshi; Kobayashi, Tomoki; Masaki, Keiichi; Kan, Hiromi; Kawaoka, Tomokazu; Tsuge, Masataka; Hiraga, Nobuhiko; Imamura, Michio; Kawakami, Yoshiiku; Aikata, Hiroshi; Takahashi, Shoichi; Akuta, Norio; Suzuki, Fumitaka; Ikeda, Kenji; Kumada, Hiromitsu; Karino, Yoshiyasu; Toyota, Joji; Tsunoda, Tatsuhiko; Kubo, Michiaki; Kamatani, Naoyuki; Nakamura, Yusuke; Chayama, Kazuaki, 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, 2014/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases, Boston, USA
  55. Nucleotide analogue improves interferon responsiveness in HBV-infected human hepatocytes, Tsuge, Masataka; Hiraga, Nobuhiko; Murakami, Eisuke; Imamura, Michio; Abe, Hiromi; Miki, Daiki; Ochi, Hidenori; Hayes, C. Nelson; Chayama, Kazuaki, 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, 2014/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases, Boston, USA
  56. Hepatitis B virus infection efficiency and immune response decreases with cell density in primary cultured hepatocytes, Hayes, C. Nelson; Abe, Hiromi; Akamatsu, Sakura; Hiraga, Nobuhiko; Imamura, Michio; Tsuge, Masataka; Miki, Daiki; Aikata, Hiroshi; Ochi, Hidenori; Ishida, Yuji; Tateno, Chise; Chayama, Kazuaki, 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, 2014/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases, Boston, USA
  57. IFNL4/IL-28B haplotype structure and predictability of their variations for spontaneous and treatment-induced clearance of HCV infection in the Japanese population, Ochi, Hidenori; Miki, Daiki; Hayes, C. Nelson; Abe, Hiromi; Kubo, Michiaki; Chayama, Kazuaki, 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, 2014/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases, Boston, USA
  58. Germline variants of highly point-mutated genes in hepatocellular carcinoma do not have strong effects on HCV-related hepatocarcinogenesis, Miki, Daiki; Ochi, Hidenori; Hayes, C. Nelson; Ono, Atsushi; Akamatsu, Sakura; Urabe, Yuji; Masaki, Keiichi; Abe, Hiromi; Kawaoka, Tomokazu; Nakahara, Takashi; Seki, Noriaki; Murakami, Eisuke; Zhang, Yizhou; Uchida, Takuro; Honda, Yohji; Kan, Hiromi; Tsuge, Masataka; Hiraga, Nobuhiko; Imamura, Michio; Kawakami, Yoshiiku; Aikata, Hiroshi; Kubo, Michiaki; Chayama, Kazuaki, 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, 2014/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases, Boston, USA
  59. Two microRNA polymorphisms are associated with hepatitis B virus-related but not hepatitis C virus-related hepatocellular carcinoma in the Japanese population, Miki, Daiki; Ochi, Hidenori; Hayes, C. Nelson; Abe, Hiromi; Kawaoka, Tomokazu; Ono, Atsushi; Akamatsu, Sakura; Nakahara, Takashi; Seki, Noriaki; Murakami, Eisuke; Zhang, Yizhou; Uchida, Takuro; Honda, Yohji; Masaki, Keiichi; Kan, Hiromi; Tsuge, Masataka; Hiraga, Nobuhiko; Imamura, Michio; Kawakami, Yoshiiku; Aikata, Hiroshi; Kubo, Michiaki; Chayama, Kazuaki, 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, 2014/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases, Boston, USA
  60. IFNL4 STIMULATES EXPRESSION OF IFN lambda S AND DIFFERENTIALLY CONTROLS BASAL EXPRESSION LEVELS OF ANTI-VIRAL ISGS AND SIGNAL SUPPRESSORS WHICH LEAD TO DIFFERENT EFFECTS OF IFN, Abe, H.; Hayes, C. N.; Miki, D.; Hiraga, N.; Imamura, M.; Tsuge, M.; Kobayashi, T.; Kawakami, Y.; Aikata, H.; Ochi, H.; Chayama, K., 49th Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver, 2014/04, Without Invitation, English, European-Association-for-the-Study-of-the-Liver, London, UK
  61. Integrative analysis of early and late changes in microRNA and gene expression profiles in human hepatocyte chimeric mice following infection with hepatitis B virus or hepatitis C virus, Hayes, C. Nelson; Akamatsu, Sakura; Tsuge, Masataka; Miki, Daiki; Hiraga, Nobuhiko; Abe, Hiromi; Imamura, Michio; Takahashi, Shoichi; Ochi, Hidenori; Chayama, Kazuaki, 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, 2013/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases, Washington, D.C., USA
  62. HLA-DQ confers susceptibility to chronic hepatitis C in Japanese: a genome-wide association study, Miki, Daiki; Ochi, Hidenori; Hayes, C. Nelson; Abe, Hiromi; Kawaoka, Tomokazu; Tsuge, Masataka; Hiraga, Nobuhiko; Imamura, Michio; Kawakami, Yoshiiku; Aikata, Hiroshi; Takahashi, Shoichi; Akuta, Norio; Suzuki, Fumitaka; Ikeda, Kenji; Kumada, Hiromitsu; Karino, Yoshiyasu; Toyota, Joji; Chayama, Kazuaki, 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, 2013/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases, Washington, D.C., USA
  63. Analysis of the usefulness of HCV core amino acid substitution, serum IP-10 level and IFNL4 genotype as the predictive factor of anti-HCV effect in triple therapy including protease inhibitor, Karino, Yoshiyasu; Nakajima, Tomoaki; Ozeki, Itaru; Hige, Shuhei; Kimura, Mutuumi; Arakawa, Tomohiro; Kuwata, Yasuaki; Sato, Takahiro; Ohmura, Takumi; Toyota, Joji; Ochi, Hidenori; Miki, Daiki; Chayama, Kazuaki, 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, 2013/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases, Washington, D.C., USA
  64. Relationship between survival rate at 10 years and virological response to IFN therapy in patients with recurrent hepatitis C after living donor liver transplantation, Kawaoka, Tomokazu; Imamura, Michio; Aikata, Hiroshi; Miki, Daiki; Ochi, Hidenori; Tashiro, Hirotaka; Ohdan, Hideki; Chayama, Kazuaki, 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, 2013/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases, Washington, D.C., USA
  65. Antiviral effect of tenofovir disoproxil fumarate on drug-resistant HBV clones and different susceptibility between HBV genotype A and C, Murakami, Eisuke; Tsuge, Masataka; Hiraga, Nobuhiko; Kawaoka, Tomokazu; Ono, Atsushi; Miki, Daiki; Abe, Hiromi; Imamura, Michio; Aikata, Hiroshi; Ochi, Hidenori; Hayes, C. Nelson; Chayama, Kazuaki, 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, 2013/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases, Washington, D.C., USA
  66. Monitoring serum HBV RNA is useful for predicting rebound of hepatitis after the discontinuation of nucleotide analogue therapy in chronic hepatitis B patients, Tsuge, Masataka; Murakami, Eisuke; Imamura, Michio; Abe, Hiromi; Miki, Daiki; Hiraga, Nobuhiko; Ochi, Hidenori; Hayes, C. Nelson; Ginba, Hiroyuki; Matsuyama, Kazuhiro; Kawakami, Hiroiku; Chayama, Kazuaki, 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, 2013/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases, Washington, D.C., USA
  67. Expression levels of IFNL4 and other IFN-lambda s are determined by dinucleotide polymorphism of IFNL4 and correlate with basal expression levels of interferon stimulated genes and effect of interferon, Abe, Hiromi; Hayes, C. Nelson; Hiraga, Nobuhiko; Imamura, Michio; Miki, Daiki; Tsuge, Masataka; Ochi, Hidenori; Chayama, Kazuaki, 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, 2013/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases, Washington, D.C., USA
  68. Early and late changes in gene expression profiles following infection with hepatitis B or C virus in human hepatocyte chimeric mice, Hayes, C. Nelson; Akamatsu, Sakura; Tsuge, Masataka; Miki, Daiki; Hiraga, Nobuhiko; Abe, Hiromi; Imamura, Michio; Takahashi, Shoichi; Ochi, Hidenori; Chayama, Kazuaki, 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, 2013/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases, Washington, D.C., USA
  69. Severe Necroinflammatory Reaction Caused by Natural Killer By Fas/FasL Interaction and Dendritic Cells in Human Hepatocyte Chimeric Mouse, Hiraga, Nobuhiko; Imamura, Michio; Hayes, C. Nelson; Tsuge, Masataka; Takahashi, Shoichi; Aikata, Hiroshi; Abe, Hiromi; Miki, Daiki; Ochi, Hidenori; Tateno, Chise; Yoshizato, Katsutoshi; Ohdan, Hideki; Chayama, Kazuaki, 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), 2012/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases (AASLD), Boston, USA
  70. Analysis of HCV genomes against direct-acting antiviral agents using human hepatocyte chimeric mice and ultra-deep sequencing, Abe, Hiromi; Hiraga, Nobuhiko; Imamura, Michio; Hayes, C. Nelson; Miki, Daiki; Tsuge, Masataka; Takahashi, Shoichi; Chayama, Kazuaki, 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), 2012/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases (AASLD), Boston, USA
  71. A functional SNP of DEPDC5 modulates gene transcription level through the allele-specific binding of FOXA1/2, Ochi, Hidenori; Yoshima, Tadahiko; Miki, Daiki; Abe, Hiromi; Hayashida, Yasufumi; Kumada, Hiromitsu; Toyota, Joji; Kamatani, Naoyuki; Nakamura, Yusuke; Chayama, Kazuaki, 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), 2012/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases (AASLD), Boston, USA
  72. Human microRNA hsa-miR-1231 suppresses hepatitis B virus replication with targeting to HB core region, Tsuge, Masataka; Kohno, Tomohiko; Hiraga, Nobuhiko; Abe, Hiromi; Miki, Daiki; Imamura, Michio; Takahashi, Shoichi; Ochi, Hidenori; Hayes, C. Nelson; Chayama, Kazuaki, 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), 2012/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases (AASLD), Boston, USA
  73. HBV core and surface proteins co-localize and interact with AGO2 in stably transfected HepG2 cells, Hayes, C. Nelson; Akamatsu, Sakura; Tsuge, Masataka; Miki, Daiki; Hiraga, Nobuhiko; Imamura, Michio; Takahashi, Shoichi; Ochi, Hidenori; Chayama, Kazuaki, 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), 2012/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases (AASLD), Boston, USA
  74. Serum miRNAs and the hepatitis B virus life cycle, Hayes, C. Nelson; Akamatsu, Sakura; Tsuge, Masataka; Miki, Daiki; Hiraga, Nobuhiko; Imamura, Michio; Takahashi, Shoichi; Ochi, Hidenori; Chayama, Kazuaki, 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), 2012/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases (AASLD), Boston, USA
  75. HEPATITIS C VIRUS INFECTION SUPPRESSES THE INTERFERON RESPONSE IN THE LIVER OF THE HUMAN HEPATOCYTE CHIMERIC MOUSE, Tsuge, Masataka; Hiraga, Nobuhiko; Abe, Hiromi; Miki, Daiki; Imamura, Michio; Takahashi, Shoichi; Ochi, Hidenori; Hayes, C. Nelson; Chayama, Kazuaki, 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), 2011/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases (AASLD), San Francisco, USA
  76. HEPATITIS C VIRUS INFECTION ALTERS EXPRESSION OF MICRORNAS INVOLVED THE INTERFERON RESPONSE IN THE LIVER OF THE HUMAN HEPATOCYTE CHIMERIC MOUSE, Hayes, C. Nelson; Tsuge, Masataka; Fujimoto, Yoshifumi; Hiraga, Nobuhiko; Abe, Hiromi; Miki, Daiki; Imamura, Michio; Takahashi, Shoichi; Ochi, Hidenori; Chayama, Kazuaki, 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), 2011/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases (AASLD), San Francisco, USA
  77. ANALYSIS OF EXPRESSION LEVELS OF INTERFERON STIMULATED GENES BY IL28B GENOTYPES IN HUMAN HEPATOCYTE CHIMERIC MICE DURING INTERFERON ALPHA TREATMENT AGAINST HEPATITIS C VIRUS INFECTION, Abe, Hiromi; Hiraga, Nobuhiko; Imamura, Michio; Hayes, C. Nelson; Miki, Daiki; Tsuge, Masataka; Takahashi, Shoichi; Ochi, Hidenori; Chayama, Kazuaki, 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), 2011/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases (AASLD), San Francisco, USA
  78. PRETREATMENT SERUM PAI-1 LEVEL IS A NOVEL PREDICTOR FOR RESPONSE TO PEGYLATED INTERFERON-alpha-2B PLUS RIBAVIRIN THERAPY IN CHRONIC HEPATITIS C VIRUS INFECTION, Miki, Daiki; Ohishi, Waka; Ochi, Hidenori; Hayes, C. Nelson; Abe, Hiromi; Hayashida, Yasufumi; Tsuge, Masataka; Imamura, Michio; Kamatani, Naoyuki; Nakamura, Yusuke; Chayama, Kazuaki, 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), 2011/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases (AASLD), San Francisco, USA
  79. A GENOME-WIDE ASSOCIATION STUDY IDENTIFIED A NOVEL SUSCEPTIBILITY LOCUS FOR HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS C VIRUS CARRIERS, Miki, Daiki; Ochi, Hidenori; Hayes, C. Nelson; Abe, Hiromi; Yoshima, Tadahiko; Hayashida, Yasufumi; Aikata, Hiroshi; Ikeda, Kenji; Kumada, Hiromitsu; Toyota, Joji; Tsunoda, Tatsuhiko; Kubo, Michiaki; Nakamura, Yusuke; Kamatani, Naoyuki; Chayama, Kazuaki, 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), 2011/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases (AASLD), San Francisco, USA
  80. IL28B BUT NOT ITPA POLYMORPHISM IS ASSOCIATED WITH RESPONSE TO PEG-INTERFERON, RIBAVIRIN AND TELAPREVIR TRIPLE THERAPY IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1, Hayes, C. Nelson; Abe, Hiromi; Miki, Daiki; Ochi, Hidenori; Karino, Yoshiyasu; Toyota, Joji; Sezaki, Hitomi; Kobayashi, Mariko; Akuta, Norio; Suzuki, Fumitaka; Kumada, Hiromitsu; Chayama, Kazuaki, 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), 2011/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases (AASLD), San Francisco, USA
  81. PRETREATMENT OF HEPATOMA CELL LINES WITH IL28B DELAYS INTERFERON-INDUCED ISG EXPRESSION, WHEREAS PRETREATMENT WITH NEUTRALIZING ANTIBODIES AGAINST IL28B REDUCES EXPRESSION LEVELS OF IFN RECEPTORS, Abe, H.; Ochi, H.; Hayes, C. N.; Miki, D.; Tsuge, M.; Hiraga, N.; Imamura, M.; Takahashi, S.; Chayama, K., 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), 2011/04, Without Invitation, English, European-Association-for-the-Study-of-the-Liver (EASL), Berlin, Germany
  82. IDENTIFICATION OF NOVEL HEPATITIS C VIRUS DELETION MUTANTS IN CHRONIC HEPATITIS C PATIENTS, Tsuge, Masataka; Kohno, Tomohiko; Ohnishi, Mayu; Abe, Hiromi; Miki, Daiki; Hiraga, Nobuhiko; Imamura, Michio; Takahashi, Shoichi; Ochi, Hidenori; Chayama, Kazuaki, 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, 2010/10, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases, Boston, USA
  83. IL-28B PREDICTS RESPONSE TO CHRONIC HEPATITIS C THERAPY IN VARIOUS REGIMEN AND VIRAL GENOTYPES - REPLICATION STUDY IN ASIAN POPULATIONS, Ochi, Hidenori; Maekawa, Toshiro; Abe, Hiromi; Hayashida, Yasufumi; Nakano, Rikita; Miki, Daiki; Imamura, Michio; Hiraga, Nobuhiko; Kawakami, Yoshiiku; Aimitsu, Shiomi; Kao, Jia-Horng; Kubo, Michiaki; Tsunoda, Tatsuhiko; Kumada, Hiromitsu; Nakamura, Yusuke; Hayes, C. Nelson; Chayama, Kazuaki, 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, 2010/10, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases, Boston, USA
  84. RECIPROCAL CONTROL OF INTERFERON STIMULATED GENE MRNAS BETWEEN POSITIVE ANTI-VIRAL EFFECTER AND NEGATIVE REGULATOR BY IL28B GENE POLYMORPHISM AND BY ANOTHER REGULATORY MECHANISM, Abe, Hiromi; Ochi, Hidenori; Miki, Daiki; Imamura, Michio; Tsuge, Masataka; Hiraga, Nobuhiko; Takahashi, Shoichi; Hayes, C. Nelson; Chayama, Kazuaki, 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, 2010/10, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases, Boston, USA
  85. ITPA GENE POLYMORPHISM AFFECTS RIBAVIRIN ASSOCIATED ANEMIA AND TREATMENT OUTCOME - A GENOME-WIDE STUDY OF JAPANESE HCV PATIENTS, Ochi, Hidenori; Maekawa, Toshiro; Abe, Hiromi; Hayashida, Yasufumi; Nakano, Rikita; Miki, Daiki; Kubo, Michiaki; Tsunoda, Tatsuhiko; Hayes, C. Nelson; Kumada, Hiromitsu; Nakamura, Yusuke; Chayama, Kazuaki, 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, 2010/10, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases, Boston, USA
  86. Characterization of a novel metalloproteinase LERP1 involved in lung and esophageal carcinogenesis, Miki D, Daigo Y, Tsunoda T, Chayama K, Nakamura Y, The 76th Annual Meeting of the Japanese Cancer Association, 2010/09/22, Without Invitation, English, Japanese Cancer Association, Osaka, Japan
  87. COMMON VARIATION OF IL28 AFFECTS INTRAHEPATIC EXPRESSION OF INTERFERON STIMULATED GENES AND CORRELATES WITH EFFECT OF PEG-INTERFERON AND RIBAVIRIN COMBINATION THERAPY, Abe, H.; Hayes, C. N.; Ochi, H.; Maekawa, T.; Tsuge, M.; Miki, D.; Mitsui, F.; Hiraga, N.; Imamura, M.; Takahashi, S.; Chayama, K., 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, 2010/04, Without Invitation, English, European-Association-for-the-Study-of-the-Liver, Vienna, Austria
  88. COMMON VARIATION OF IL28 AFFECTS GAMMA-GTP LEVELS AND INFLAMMATION OF THE LIVER IN CHRONICALLY HEPATITIS C VIRUS INFECTED PATIENTS, Abe, H.; Hayes, C. N.; Ochi, H.; Maekawa, T.; Tsuge, M.; Miki, D.; Mitsui, F.; Hiraga, N.; Imamura, M.; Takahashi, S.; Chayama, K., 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, 2010/04, Without Invitation, English, European-Association-for-the-Study-of-the-Liver, Vienna, Austria
  89. Characterization of a novel secreted oncoprotein LERP1 involved in lung and esophageal carcinogenesis, Miki D, Daigo Y, Chayama K, Nakamura Y, 8th Joint Conference of the American Association for Cancer Research and the Japanese Cancer Association, 2010/02/09, Without Invitation, English, American Association for Cancer Research & Japanese Cancer Association, Hawaii, USA
  90. TELAPREVIR TREATMENT IN COMBINATION WITH INTERFERON-ALPHA TO A HUMAN HEPATOCYTE CHIMERIC MOUSE WITH HEPATITIS C VIRUS INFECTION, Iwoo, Eiji; Imamura, Michio; Hiraga, Nobuhiko; Kimura, Takashi; Miki, Daiki; Hatakeyama, Tsuyoshi; Mitsui, Fukiko; Tsuge, Masataka; Kamiya, Naohiro; Takahashi, Shoichi; Chayama, Kazuaki, 59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, 2008/10, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases, San Francisco, USA
  91. Clinical features of non-B non-C hepatocellular carcinoma, Miki D, Aikata H, Uka K, Takaki S, Yamashina K, Tei S, Kodama H, Takahashi S, Chayama K, The 17th Conference of the Asian Pacific Association for the Study of the Liver, 2007/03/30, Without Invitation, English, Asian Pacific Association for the Study of the Liver (APASL), Kyoto, Japan
  92. Radiofrequency ablation combined with transcatheter arterial chemoembolization for small hepatocellular carcinomas, Aikata, Hiroshi; Shirakawa, Hiroo; Takaki, Shintaro; Uka, Kiminori; Miki, Daiki; Yamashina, Keitaro; Hiramatsu, Akira; Takahashi, Shoichi; Chayama, Kazuaki, 57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, 2006/10, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases, Boston, USA
  93. Imbalance between angiotensin II type 1 and 2 receptor signals is a key factor in pathogenesis of liver fibrosis: A novel target for therapeutic strategy of fibrotic liver diseases in metabolic syndome, Tazuma, Susumu; Hyogo, Hideyuki; Kanno, Keishi; Nabeshima, Yoshitaka; Kobuke, Toshiya; Komichi, Daisuke; Nonaka, Michihiro; Inoue, Motoki; Iwamoto, Keiko; Ishitobi, Tomokazu; Ajima, Takeyoshi; Miki, Daiki; Chayama, Kazuaki, Digestive Disease Week Meeting/107th Annual Meeting of the American-Gastroenterlogical-Association, 2006/05, Without Invitation, English, American-Gastroenterlogical-Association, Los Angeles, USA
  94. Hepatocytoprotection by tauroursodeoxycholate (TUDC) against peroxisome proliferators-activated receptor gamma (Ppar gamma) ligand-induced liver damage through ERK signaling pathway: Clinical implication of pleiotropic action of troglitazone (TGZ), Nonaka, Michihiro; Tazuma, Susumu; Hyogo, Hideyuki; Komichi, Daisuke; Kobuke, Toshiya; Inoue, Motoki; Iwamoto, Keiko; Nabeshima, Yoshitaka; Ishitobi, Tomokazu; Ajima, Takeyoshi; Miki, Daiki; Yamamoto, Hiroya; Chayama, Kazuaki, Digestive Disease Week Meeting/107th Annual Meeting of the American-Gastroenterlogical-Association, 2006/05, Without Invitation, English, American-Gastroenterlogical-Association, Los Angeles, USA
  95. Pravastatin, a HMG-CoA reductase inhibitor, attenuates hepatic oxidative stress to retard liver fibrogenesis of nonalcoholic fatty liver diseases in an in vivo study: An evidence for therapeutic potential of statin on nonalcoholic steatohepatitis, Inoue, Motoki; Tazuma, Susumu; Hyogo, Hideyuki; Komichi, Daisuke; Kobuke, Toshiya; Nonaka, Michihiro; Iwamoto, Keiko; Nabeshima, Yoshitaka; Ishitobi, Tomokazu; Ajima, Takeyoshi; Miki, Daiki; Yamamoto, Hiroya; Chayama, Kazuaki, Digestive Disease Week Meeting/107th Annual Meeting of the American-Gastroenterlogical-Association, 2006/05, Without Invitation, English, American-Gastroenterlogical-Association, Los Angeles, USA

Awards

  1. 2021/04/15, Incitement Award of the Japanese Society of Gastroenterology, The Japanese Society of Gastroenterology, PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication
  2. 2013/11/05, Presidential Poster of Distinction, The American Association for the Study of Liver Diseases, HLA-DQ confers susceptibility to chronic hepatitis C in Japanese: a genome-wide association study
  3. 2012/10/10, 5th CHUGAI Award of the Japanese Society of Hepatology, The Japanese Society of Hepatology, Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers
  4. 2011/11/05, Young Investigator Liver Cancer Research Award, The American Association for the Study of Liver Diseases, A genome-wide association study identified a novel susceptibility locus for hepatocellular carcinoma in chronic hepatitis C virus carriers
  5. 2011/10/05, Incitement Award of the Japanese Cancer Association, The Japanese Cancer Association, Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations
  6. 2011/06/11, 14th KOUJIN Award for Basic Medical Research, Alumni association KOUJIN of Department of Medicine at Hiroshima University, Genome-wide association studies for liver diseases and responsiveness to therapy in Japanese or East Asian populations
  7. 2008/06/06, Abstract Award, The Japanese Society of Hepatology, The effects of amino acid substitutions in HCV core and ISDR regions on infectivity in human hepatocyte chimeric mice

Patented

  1. Patent, 5924644, 2016/04/28

External Funds

Acceptance Results of Competitive Funds

  1. Grant-in-Aid for Scientific Research (A), Grant-in-Aid for Scientific Research (KAKENHI), 2021/04/01, 2024/03/31
  2. Research Program on Hepatitis (Program on the Innovative Development and the Application of New Drugs for Hepatitis B), Research for HBV therapy development based on the establishment of HBV-sensitive cell and animal models, 2021/04/01, 2022/03/31
  3. Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (KAKENHI), Risk prediction for development of non-viral hepatocellular carcinoma using the human genome and microbiome by machine learning, 2020/04/01, 2023/03/31
  4. Research Program on Hepatitis (Program for Basic and Clinical Research on Hepatitis), Study of factors associated with health status and prognosis after successful HCV eradication, 2020/04/01, 2023/03/31
  5. Research Program on Hepatitis (Program on the Innovative Development and the Application of New Drugs for Hepatitis B), Analysis of HBV life cycle by using sophisticated reporter HBV systems and its application to the development of a new strategy to suppress HBV infection and replication, 2020/04/01, 2022/03/31
  6. Research Program on Hepatitis (Program for Basic and Clinical Research on Hepatitis), Study of outcome of liver cirrhotic patients received HCV elimination therapy, 2019/04/01, 2022/03/31
  7. Research Program on Hepatitis (Program on the Innovative Development and the Application of New Drugs for Hepatitis B), Hepatitis B virus eradication therapy development using a highly efficient cell culture system and a long term active chronic hepatitis B mouse model, 2017/04/01, 2022/03/31
  8. Research Program on Hepatitis, 2017/04/01, 2020/03/31
  9. Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (KAKENHI), Identification of novel genetic factors and genetic risk assessment models for non-viral HCC, 2017/04/01, 2020/03/31
  10. Challenging Research (Pioneering), Grant-in-Aid for Scientific Research (KAKENHI), 2017/04/01, 2020/03/31
  11. JST Strategic Basic Research Programs, CREST (Create Research for Evolutional Science and Technology), Exploring etiologies, sub-classification, and risk prediction of diseases based on big-data analysis of clinical and whole omics data in medicine, 2018/04/01, 2020/03/31
  12. Joint Reseach Project between Higashihiroshima City and Hiroshima University, Development of Japanese sake-related functional foods which can modify gut flora in Higashihiroshima City, 2018/06/01, 2019/03/31
  13. Bristol-Myers Squibb Foundation Grants, A study of the effect of dysbiosis on peripheral blood microvesicles in patients with liver diseases and the application as biomarkers, 2017/11/01, 2019/03/31
  14. Research Grant, Identification of host genetic factors and genetic risk assessment models for development of HCC after HCV eradication, 2017/03/01, 2018/03/31
  15. Research Grant, Identification of HCC-specific exosomes and exosomal miRNAs, 2016/11/01, 2018/03/31
  16. Bristol-Myers Squibb Foundation Grants, Immunogenomics approach to clarify the mechanism of hepatocarcinogenesis, 2016/11/01, 2018/03/31
  17. Research Grant, Integrative multi-omics analysis of interactions between obesity, diabetes mellites and NASH, 2015/04/01, 2017/03/31
  18. Grant-in-Aid for Scientific Research, 2014/04/01, 2017/03/31
  19. Grant-in-Aid for Young Scientists (B), Grant-in-Aid for Scientific Research (KAKENHI), The effects of genetic polymorphisms in viral sensing pathways on the development of viral hepatitis, 2014/04/01, 2017/03/31
  20. Grant-in-Aid for Scientific Research, Comprehensive analysis of miRNA polymorphisms which affect clinical and pathological conditions in chronic viral hepatitis, 2013/04/01, 2016/03/31
  21. Grant-in-aid for attending the international conference, A genome-wide association study identified a novel susceptibility locus for hepatocellular carcinoma in chronic hepatitis C virus carriers (AASLD 2011, San Francisco), 2011/11/05, 2011/11/09

Social Activities

History as Committee Members

  1. Councilor of the West Branch, 2021/04, 2022/03, The Japanese Society of Hepatology
  2. Councilor of the West Branch, 2020/04, 2021/03, The Japanese Society of Hepatology
  3. Councilor of the West Branch, 2019/04, 2020/03, The Japanese Society of Hepatology
  4. Councilor of the West Branch, 2018/04, 2019/03, The Japanese Society of Hepatology
  5. Councilor of the West Branch, 2017/04, 2018/03, The Japanese Society of Hepatology
  6. Councilor of the Chugoku Branch, The Japanese Society of Gastroenterology

History as Peer Reviews of Academic Papers

  1. 2021, Journal of Advanced Research, Others, Reviewer, 1
  2. 2021, EBioMedicine, Others, Reviewer, 1
  3. 2021, Frontiers in Immunology, Others, Reviewer, 1
  4. 2021, Journal of Gastroenterology, Others, Reviewer, 1
  5. 2021, Cancer Science, Others, Reviewer, 1
  6. 2021, Immunologic Research, Others, Reviewer, 1
  7. 2020, Journal of Gastroenterology, Others, Reviewer, 2
  8. 2020, Cancer Science, Others, Reviewer, 1
  9. 2020, Journal of Viral Hepatitis, Others, Reviewer, 1
  10. 2020, Hepatology Research, Others, Reviewer, 2
  11. 2020, Immunobiology, Others, Reviewer, 1
  12. 2020, BioMed Research International, Others, Reviewer, 1
  13. 2019, EBioMedicine, Others, Reviewer, 1
  14. 2019, Journal of Gastroenterology, Others, Reviewer, 1
  15. 2019, Journal of Human Genetics, Others, Reviewer, 1
  16. 2019, Hepatology Research, Others, Reviewer, 1
  17. 2018, Journal of Clinical Investigation, Others, Reviewer, 1
  18. 2018, Cancer Science, Others, Reviewer, 1
  19. 2018, Computational and Structural Biotechnology Journal, Others, Reviewer, 1
  20. 2018, Hepatology Research, Others, Reviewer, 1
  21. 2018, Disease Markers, Others, Reviewer, 1
  22. 2018, Journal of Human Genetics, Others, Reviewer, 3
  23. 2018, Infection, Genetics and Evolution, Others, Reviewer, 1
  24. 2017, Journal of Clinical Investigation, Others, Reviewer, 1
  25. 2017, Hepatology Research, Others, Reviewer, 1
  26. 2017, Journal of Human Genetics, Others, Reviewer, 2
  27. 2017, Journal of Virological Methods, Others, Reviewer, 1
  28. 2016, Journal of Gastroenterology, Others, Reviewer, 1
  29. 2016, Hepatology Research, Others, Reviewer, 2
  30. 2016, Human Immunology, Others, Reviewer, 1
  31. 2015, Cancer Science, Others, Reviewer, 1
  32. 2015, Journal of Human Genetics, Others, Reviewer, 1
  33. 2014, Journal of Human Genetics, Others, Reviewer, 1
  34. 2012, Cancer Science, Others, Reviewer, 1